

Pharmacology and Therapeutics Advisory Committee

Objective advice to Pharmac

www.pharmac.govt.nz

Pharmacology and Therapeutics Advisory Committee Provisional Recommendations 12 & 13 February 2026

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac's website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Aprepitant 40 mg tablet for people at high risk of post-operative nausea and vomiting (PONV)	Medium Priority
Abemaciclib for the treatment of people with hormone receptor positive, HER2 negative metastatic breast cancer	Cost Neutral**
Pembrolizumab (with pemetrexed) for malignant pleural mesothelioma, unresected advanced, 1 st line <ul style="list-style-type: none"> non-epithelioid histological subtypes all histological subtypes 	Withheld*
Nivolumab + Ipilimumab for malignant pleural mesothelioma, unresected advanced, 1 st line <ul style="list-style-type: none"> non-epithelioid histological subtypes all histological subtypes 	Withheld*
Testosterone cream (AndroFeme 1) for hypoactive sexual desire dysfunction (HSDD) in postmenopausal women	Low Priority
International Normalized Ratio (INR) testing equipment for people who require long-term anticoagulation management on warfarin	High Priority
Salbutamol dry powder inhaler for Chronic Obstructive Pulmonary Disease (COPD) and asthma	Cost Neutral**
Whey Protein Concentrate (Unflavoured) as a protein supplement for protein losing enteropathy, high protein needs, or use as a component in a modular formula	Cost Neutral**
Fortisip Plant Based for people who need oral nutrition support, vegan option	Cost Neutral**
Tadalafil for the treatment of pulmonary arterial hypertension , Raynards syndrome and people undergoing cardiac surgery	Cost Neutral**

Sodium chloride oral liquid 2mmol/mL for use in babies and children as a sodium replacement	Cost Neutral**
---	----------------

*Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until full record is available.

**Cost Neutral – The Committee has recommended this application be funded if the cost is neutral to the provision of the currently funded medicine(s), including the related health system costs

[More information about the agenda items considered at the recent Pharmacology and Therapeutics Advisory Committee meeting can be found on the Pharmac website](#)

Released 18 March 2026